Dr. Paul Auwaerter discusses new and evolving COVID-19 subvariants. Topics: *Subvariants impact on treatment efficacy *Will evolving subvariants lead to increased cases and hospitalizations? *Vaccine availability and who needs boosters *CDC change to isolation recommendation *What to expect from influenza and RSV this year
Faculty
Clinical Director, Division of Infectious Diseases
Sherrilyn and Ken Fisher Professor of Medicine
Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine